open access

Vol 12, No 3 (2019)
Congress abstract / Abstract
Get Citation

Relationship between the expression of CD69 on the surface of lymphocytes T and B from peripheral blood and bone marrow of patients with chronic lymphocytic leukemia and selected prognostic factors

Agnieszka Grafka, Ewelina Grywalska, Jacek Roliński, Elżbieta Starosławska
Journal of Transfusion Medicine 2019;12(3):126-126.

open access

Vol 12, No 3 (2019)
PRACA ORYGINALNA — STRESZCZENIE

Abstract

Background. Chronic lymphocytic leukemia — CLL is a monoclonal B-cell lymphocytosis most commonly diagnosed in adults. The commonly known prognostic factors of this leukemia are: clinical stage according to the Raia or Bineta scale, lymphocytosis doubling time (LDT), thymidine kinase level and b2-microglobulin. The new prognostic markers of CLL are still being sought. The aim of the study was to assess the percentage and absolute number of activated B and T lymphocytes of peripheral blood and bone marrow of CLL patients and the correlation between lymphocytes expressing the CD69 marker and selected prognostic factors of CLL. Material and methods. The study comprised 150 persons; 120 untreated patients with CLL and 30 healthy people as control. Peripheral blood was collected from control patients to assess the immunophenotype of lymphocytes. CLL diagnosis was based on clinical examination, morphology and immunophenotype of peripheral blood lymphocytes and bone marrow examination. Mononuclear cells were isolated from blood and bone marrow to evaluate the immunophenotype using cytometric method. Results. CLL patients had a higher absolute count of B and T lymphocytes expressing the CD69 antigen as compared to healthy subjects. Evaluation of the percentage of CD19 + B cell peripheral blood and bone marrow expressing the early marker of CD69 activation showed association with the Rai stage. A negative correlation was demonstrated between the percentage of CD3 + CD69 + T cells in peripheral blood and lymphocyte doubling time. Patients with lymphocyte doubling time had a higher percentage of CD3 + CD69 + T cells. It has been demonstrated that a higher percentage of CD19 + CD69 + lymphocytes appeared when therapy was administered due to rapid progress of the disease as compare to untreated cases. Conclusions. Assessment of the number of T and B lymphocytes expressing the CD69 antigen is a valuable support for the cytometric diagnosis of CLL. Apart from the already known prognostic factors, patients should be assessed for the number of activated lymphocytes, thus the clinical picture of the patient will be more complete.

Abstract

Background. Chronic lymphocytic leukemia — CLL is a monoclonal B-cell lymphocytosis most commonly diagnosed in adults. The commonly known prognostic factors of this leukemia are: clinical stage according to the Raia or Bineta scale, lymphocytosis doubling time (LDT), thymidine kinase level and b2-microglobulin. The new prognostic markers of CLL are still being sought. The aim of the study was to assess the percentage and absolute number of activated B and T lymphocytes of peripheral blood and bone marrow of CLL patients and the correlation between lymphocytes expressing the CD69 marker and selected prognostic factors of CLL. Material and methods. The study comprised 150 persons; 120 untreated patients with CLL and 30 healthy people as control. Peripheral blood was collected from control patients to assess the immunophenotype of lymphocytes. CLL diagnosis was based on clinical examination, morphology and immunophenotype of peripheral blood lymphocytes and bone marrow examination. Mononuclear cells were isolated from blood and bone marrow to evaluate the immunophenotype using cytometric method. Results. CLL patients had a higher absolute count of B and T lymphocytes expressing the CD69 antigen as compared to healthy subjects. Evaluation of the percentage of CD19 + B cell peripheral blood and bone marrow expressing the early marker of CD69 activation showed association with the Rai stage. A negative correlation was demonstrated between the percentage of CD3 + CD69 + T cells in peripheral blood and lymphocyte doubling time. Patients with lymphocyte doubling time had a higher percentage of CD3 + CD69 + T cells. It has been demonstrated that a higher percentage of CD19 + CD69 + lymphocytes appeared when therapy was administered due to rapid progress of the disease as compare to untreated cases. Conclusions. Assessment of the number of T and B lymphocytes expressing the CD69 antigen is a valuable support for the cytometric diagnosis of CLL. Apart from the already known prognostic factors, patients should be assessed for the number of activated lymphocytes, thus the clinical picture of the patient will be more complete.

Get Citation

Keywords

chronic lymphocytic leukemia; CD69 antigen; prognostic factors

About this article
Title

Relationship between the expression of CD69 on the surface of lymphocytes T and B from peripheral blood and bone marrow of patients with chronic lymphocytic leukemia and selected prognostic factors

Journal

Journal of Transfusion Medicine

Issue

Vol 12, No 3 (2019)

Article type

Congress abstract / Abstract

Pages

126-126

Bibliographic record

Journal of Transfusion Medicine 2019;12(3):126-126.

Keywords

chronic lymphocytic leukemia
CD69 antigen
prognostic factors

Authors

Agnieszka Grafka
Ewelina Grywalska
Jacek Roliński
Elżbieta Starosławska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Journal of Transfusion Medicine dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl